[go: up one dir, main page]

CA2070659A1 - Preparation d'anticorps - Google Patents

Preparation d'anticorps

Info

Publication number
CA2070659A1
CA2070659A1 CA002070659A CA2070659A CA2070659A1 CA 2070659 A1 CA2070659 A1 CA 2070659A1 CA 002070659 A CA002070659 A CA 002070659A CA 2070659 A CA2070659 A CA 2070659A CA 2070659 A1 CA2070659 A1 CA 2070659A1
Authority
CA
Canada
Prior art keywords
ser
tyr
gly
asp
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002070659A
Other languages
English (en)
Other versions
CA2070659C (fr
Inventor
Scott D. Gorman
Edward G. Routledge
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2070659A1 publication Critical patent/CA2070659A1/fr
Application granted granted Critical
Publication of CA2070659C publication Critical patent/CA2070659C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002070659A 1990-10-05 1991-10-04 Preparation d'anticorps Expired - Lifetime CA2070659C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9021679.7 1990-10-05
GB909021679A GB9021679D0 (en) 1990-10-05 1990-10-05 Antibody preparation
PCT/GB1991/001726 WO1992006193A1 (fr) 1990-10-05 1991-10-04 Anticorps a efficacite antigoniste a l'antigene cd3

Publications (2)

Publication Number Publication Date
CA2070659A1 true CA2070659A1 (fr) 1992-04-06
CA2070659C CA2070659C (fr) 2001-04-24

Family

ID=10683287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002070659A Expired - Lifetime CA2070659C (fr) 1990-10-05 1991-10-04 Preparation d'anticorps

Country Status (12)

Country Link
EP (1) EP0504350B1 (fr)
JP (1) JP3081641B2 (fr)
KR (1) KR100245564B1 (fr)
AT (1) ATE169058T1 (fr)
AU (1) AU651623B2 (fr)
CA (1) CA2070659C (fr)
DE (1) DE69129896T2 (fr)
ES (1) ES2121788T3 (fr)
GB (2) GB9021679D0 (fr)
NZ (1) NZ240080A (fr)
WO (1) WO1992006193A1 (fr)
ZA (1) ZA917960B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
CA2065658A1 (fr) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugues de liposomes ou microbilles et anticorps specifiques pour les lymphocytes t et leur utilisation in vivo en tant que modulateurs de l'immunite
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE69840998D1 (de) 1997-04-30 2009-09-03 Twinstrand Therapeutics Inc Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
CA2305716A1 (fr) 1999-05-28 2000-11-28 University Of Guelph Methode de dosage biologique du wbpm
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
JP2006511194A (ja) 2002-05-02 2006-04-06 デイビッド ラブジョイ テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
US7871768B2 (en) 2003-08-04 2011-01-18 The Hospital For Sick Children Lafora's disease gene
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
WO2006087196A2 (fr) 2005-02-16 2006-08-24 University Of Zürich Methodes de traitement du cancer faisant appel a une immunotoxine amelioree
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
EP2066351B1 (fr) * 2006-10-02 2015-09-09 E. R. Squibb & Sons, L.L.C. Anticorps humains qui se lient au cxcr4, et leurs utilisations
CN101522219A (zh) 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
WO2008063933A2 (fr) 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Modulateurs de pak
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
ES2541454T3 (es) 2007-03-02 2015-07-20 Wyeth Llc Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2344180A2 (fr) 2008-09-23 2011-07-20 Wyeth LLC Procédés pour prédire la production de signaux d activation par des protéines de liaison réticulée
CA2739352C (fr) 2008-10-29 2021-07-13 Wyeth Llc Procedes de purification de molecules de liaison d'antigene monodomaines
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
WO2010091182A2 (fr) 2009-02-04 2010-08-12 Molecular Innovations Procédés pour cribler des agents candidats pour la modulation de la prorénine et de la rénine, tests de détection de la prorénine, et anticorps qu'ils emploient
ES2495367T3 (es) 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticuerpos monoclonales de ERG
US20120226119A1 (en) 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2420250A1 (fr) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anticorps anti-syndecan-4
CA2807607A1 (fr) 2010-08-20 2012-02-23 Wyeth Llc Culture cellulaire de cellules adaptees exemptes de facteur de croissance
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
RU2663794C2 (ru) 2011-10-21 2018-08-09 Пфайзер Инк. Добавление железа для улучшения культивирования клеток
EP2897631A4 (fr) 2012-08-31 2016-10-05 Univ Virginia Patent Found Peptides cibles pour l'immunothérapie et le diagnostic
EP4088737A3 (fr) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Peptides cibles pour la thérapie et les diagnostics du cancer colorectal
EP2903692B1 (fr) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine
HK1216153A1 (zh) 2012-12-13 2016-10-21 University Of Virginia Patent Foundation 用於卵巢癌治疗和诊断的靶向肽
EP4067383A1 (fr) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Anticorps multispécifiques, anticorps activables multispécifiques et leurs procédés d'utilisation
ES3005909T3 (en) 2014-03-19 2025-03-17 Pfizer Method of cell culture
WO2015160928A2 (fr) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation
WO2016014974A2 (fr) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
EP3353313B1 (fr) 2015-09-23 2024-08-07 Pfizer Inc. Cellules et procédé de culture cellulaire
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
JP7253923B2 (ja) 2016-04-05 2023-04-07 ファイザー・インク 細胞培養プロセス
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
CN111868223A (zh) 2017-09-15 2020-10-30 百时美施贵宝公司 大规模生产目的多肽过程中的在线生物质电容监测
EP3743101A2 (fr) 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Polymersomes comprenant un antigène encapsulé soluble, procédés de fabrication et utilisations associés
WO2019178489A1 (fr) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Réduction de l'activité enzymatique métabolique et de la liaison disulfure lors de la production de protéines
RS64431B1 (sr) 2018-03-26 2023-09-29 Glycanostics S R O Sredstva i postupci za glikoprofilisanje proteina
US20220105176A1 (en) 2018-09-12 2022-04-07 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
US20220073942A1 (en) 2018-12-06 2022-03-10 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
WO2021044009A1 (fr) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Inhibiteurs herv destinés à être utilisés dans le traitement des taupathies
CN117440798A (zh) 2021-04-12 2024-01-23 Acm 生物实验室私人有限公司 包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途
JP2024529771A (ja) 2021-08-26 2024-08-08 グリカノスティクス エス．アール．オー． がん診断のための糖タンパク質バイオマーカー
AU2022346688A1 (en) 2021-09-14 2024-04-04 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023079058A1 (fr) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Culture cellulaire avec production réduite de lactate
US20250304911A1 (en) 2022-02-02 2025-10-02 Pfizer Inc. Cysteine prototrophy
CN115073602B (zh) * 2022-05-30 2023-10-03 苏州百道医疗科技有限公司 一种抗cd3重组兔单克隆抗体及其应用
WO2024218706A1 (fr) 2023-04-21 2024-10-24 Pfizer Inc. Cellules et cultures cellulaires améliorées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation

Also Published As

Publication number Publication date
NZ240080A (en) 1995-05-26
DE69129896D1 (de) 1998-09-03
JP3081641B2 (ja) 2000-08-28
WO1992006193A1 (fr) 1992-04-16
CA2070659C (fr) 2001-04-24
AU8546891A (en) 1992-04-28
ES2121788T3 (es) 1998-12-16
EP0504350A1 (fr) 1992-09-23
KR100245564B1 (ko) 2000-02-15
KR927003816A (ko) 1992-12-18
ZA917960B (en) 1993-04-05
EP0504350B1 (fr) 1998-07-29
GB2249310A (en) 1992-05-06
ATE169058T1 (de) 1998-08-15
GB9021679D0 (en) 1990-11-21
GB9121126D0 (en) 1991-11-13
DE69129896T2 (de) 1998-12-10
AU651623B2 (en) 1994-07-28
JPH05502384A (ja) 1993-04-28
GB2249310B (en) 1994-08-03

Similar Documents

Publication Publication Date Title
CA2070659A1 (fr) Preparation d'anticorps
CA2109815A1 (fr) Preparation d'anticorps
CA2212750A1 (fr) Anticorps humanises contre cd3
CA2103059A1 (fr) Methode de production d'anticorps humanises
GR1002306B (el) Αναλυση και διαταξη συγκολλησεως στηλης.
CA2091769A1 (fr) Anticorps de structure mutants et leur preparation
CA2006865A1 (fr) Immunoglobulines humaines specifiques des recepteurs il-2
CA2178642A1 (fr) Complexes metalliques de coordination ion-ligand, anticorps diriges contre ceux-ci, et dosages effectues avec ces anticorps
EP0458841A4 (en) Method for the use and synthesis of peptides
CA2182013A1 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
AU3242389A (en) Novel antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
CA2295604A1 (fr) Anticorps dirige contre lo-cd2a et utilisation de celui-ci pour inhiber l'activation et la proliferation des lymphocytes t
AU3657693A (en) Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therfor
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
WO1994021812A3 (fr) Molecules de liaison specifiques aux mutants liberes par l'hepatite b
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
EP0390460A3 (fr) Antigène spécifique pour Giardia lambila, anticorps monospécifiques contre cet antigène et procédé pour détecter de la giardiase
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
CA2095735A1 (fr) Anticorps monoclonaux du virus de l'hepatite c et methode d'utilisation de ces derniers
CA2262546A1 (fr) Anticorps lo-cd2a et son utilisation pour inhiber l'activation et la proliferation de cellules t
AR243932A1 (es) Hibridoma, procedimiento para la preparacion, anticuerpo monoclonal, procedimiento para su preparacion y composicion para diagnostico de base a dicho anticuerpo.
CA2008735A1 (fr) Sequences receptrice du facteur de croissance epidermique humain (fce) et anticorps monoclonaux competitifs du fce
AU619080B2 (en) 2,4-dihalogeno-6-pyridylethanolphenylisopropylamines, processes for their preparation and their use for shifting the protein-fat ratio in favour of protein
CS8901601A1 (en) 12/g5 hybridoma producing monoclonal antibody against louping ill virus

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry